Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 29, 2018 ($M)

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.

Company Info

Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Health Care
HQ Location
Kenilworth, N.J.
Years on Fortune 500 List24
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Merck Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$40,122.000.8%
Profits ($M)$2,394.00-38.9%
Assets ($M)$87,872.00-
Total Stockholder Equity ($M)$34,336.00-
Market Value — as of March 29, 2018 ($M)$146,861.50-

Profit Ratios

Profit as % of Revenues6%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.87
EPS % Change (from 2016)-38.3%
EPS % Change (5 year annual rate)-15.3%
EPS % Change (10 year annual rate)-5.2%

Total Return

Total Return to Investors (2017)-1.5%
Total Return to Investors (5 year, annualized)10.1%
Total Return to Investors (10 year, annualized)3.5%